|
|
 |
For Proven Fracture Reduction Prescribe Reclast for Patients
For the Treatment of Women With Postmenopausal Osteoporosis. A 5 mg, Once-yearly, 15-minute Infusion of Proven Fracture Reduction.
 |
 |
3-year, multinational, randomized, double-blind, placebo-controlled study |
|
|
|
7,736 women aged 65-89 years from 239 clinical centers in 27 countries given a 15-minute infusion of Reclast or placebo infusion once a year for 3 years |
|
|
|
All women received 1000-1500 mg elemental calcium plus 400-1200 IU vitamin D supplementation per day |
Risk reduction at 3 years*:
|
|
70% (ARR 7.6%) in vertebral fracture |
|
|
|
41% (ARR 1.1%) in hip fracture |
|
|
|
25% (ARR 2.7%) in nonvertebral fracture† |
|
|
|
|
All Reclast data obtained with 5 mg once-yearly dose |
|
|
|
Fracture data for other bisphosphonates obtained using daily dosing (not most-prescribed dosing) |
*Relative to placebo.
†Nonvertebral fracture includes wrist, rib, arm, shoulder and hip fracture; excludes finger, toe and craniofacial fracture.
‡Data not from head-to-head trials.
Trademarks are the property of their respective owners.
|
|
|
|
|
